The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Daiichi Sankyo and AstraZeneca's drug, Enhertu (Trastuzumab Deruxtecan), for the treatment of unresectable or metastatic HER2-positive solid tumors. This marks a significant milestone as it is the first time an antibody-drug conjugate (ADC) has received a tumor-agnostic label, indicating its potential use across a broad range of solid tumor types. The approval, which involves companies $DSNKY and $AZN, is based on the drug's ability to target HER2-positive tumors, a common type of cancer marker.
The U.S. Food and Drug Administration on Friday gave accelerated approval for the expanded use of Daiichi Sankyo and AstraZeneca's drug to treat patients with a type of solid tumor. https://t.co/kdcJYSWxmL https://t.co/kdcJYSWxmL
1st pan-tumor ADC approval- grail “FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors” https://t.co/BJKZnGUIM5 https://t.co/lb9OO9B1Oe
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors https://t.co/ec6NfYOdBM https://t.co/fdQK6Muqnk
The U.S. Food and Drug Administration on Friday gave accelerated approval for the expanded use of Daiichi Sankyo and AstraZeneca's drug to treat patients with a type of solid tumor. https://t.co/wouHtU9Hgv https://t.co/wouHtU9Hgv
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2+ Solid Tumors!! 👏 https://t.co/7QMJyyHuTk via @onclive
FDA approves Enhertu for all HER-2 positive solid tumors. $DSNKY $AZN That's a bit of history - the first ADC granted a tumor-agnostic label. https://t.co/pkpPNiMb1U